IntelliGenome and NL Diagnóstica join forces to bring CRISPR-based tuberculosis diagnostic tools to the Brazilian market, marking a strategic expansion for both firms ahead of the UNION World Conference.
IntelliGenome is expanding its international footprint by securing an exclusive distribution partnership with NL Diagnóstica to introduce its CRISPR-based molecular diagnostic technology into the Brazilian market. The collaboration is set to be highlighted at the UNION World Conference on Lung Health, signaling a strategic move to address tuberculosis detection needs in South America.
The partnership focuses on the exclusive distribution of IntelliGenome's CRISPR-based molecular diagnostic technology for tuberculosis detection in Brazil.
NL Diagnóstica is strengthening its diagnostic portfolio by integrating IntelliGenome's advanced CRISPR-based molecular diagnostic tools. By securing exclusive distribution rights for the Brazilian market, the company positions itself to capture market share in the tuberculosis screening sector, leveraging the upcoming UNION World Conference to build industry visibility.
NL Diagnóstica serves as the exclusive distributor for IntelliGenome's diagnostic technologies within Brazil.
IntelliGenome, Inc. has secured an exclusive distribution agreement with Brazil-based NL Diagnóstica to deploy its CRISPR-based tuberculosis detection technology. The partnership aims to accelerate diagnostic capabilities across the region, with a formal showcase scheduled for the UNION World Conference on Lung Health in Rio de Janeiro.
The partnership focuses on the exclusive distribution of IntelliGenome's CRISPR-based molecular diagnostic technology for tuberculosis within Brazil.
The companies plan to showcase their joint diagnostic efforts at the UNION World Conference on Lung Health held in Rio de Janeiro.